Security Snapshot

Novartis AG - Common Stock - Foreign Institutional Ownership

CUSIP: 007103065

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

2

Shares (Excl. Options)

503,667

Price

$156.79

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 4 signals
Portfolio coverage rank
0%
Share change
+25,081
Value change
+$3,929,133
Number of holders
2
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$156.79
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 007103065 - Novartis AG - Common Stock - Foreign is tracked under CUSIP 007103065.
  • 2 institutions reported positions in Q2 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 2 to 2 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $72,321,868 to $78,908,990.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q2 2026.

Open SEC evidence

Security key

007103065

Latest holder period

Q2 2026

13F holders

2

13D/G owners

0

CIK / CUSIP context first

As of 30 Jun 2026, 2 institutional investors reported holding 503,667 shares of Novartis AG - Common Stock - Foreign.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
48
Latest
Q2 2026
Rows shown
1-25 of 48
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 503,667 $78,908,990 +$3,929,133 $156.79 2
2026 Q1 478,586 $72,321,868 +$8,052,768 $150.78 2
2025 Q4 425,309 $58,847,889 -$1,632,268 $138.35 2
2025 Q3 437,106 $54,976,712 -$477,211 $125.80 2
2025 Q2 440,894 $53,424,708 +$49,093,182 $121.01 2
2025 Q1 35,851 $3,964,582 -$2,197,479 $110.59 2
2024 Q4 58,301 $5,706,211 +$3,137,604 $97.88 3
2024 Q3 26,244 $3,022,345 +$30,304 $114.98 2
2024 Q2 25,980 $2,780,434 -$460,195 $107.03 2
2024 Q1 30,280 $2,937,222 +$1,063,719 $96.94 2
2023 Q4 19,314 $1,947,578 -$77,141 $100.84 1
2023 Q3 20,079 $2,060,358 +$1,094,363 $102.61 1
2023 Q2 9,414 $947,030 $100.60 1
2023 Q1 9,414 $863,135 -$660,141 $91.69 1
2022 Q4 16,614 $1,501,042 +$200,031 $90.35 1
2022 Q3 14,400 $1,105,036 $76.74 1
2022 Q2 14,400 $1,216,107 -$28,223,893 $84.45 1
2022 Q1 323,370 $29,440,000 +$1,477,781 $91.04 1
2021 Q4 307,138 $27,993,000 +$3,454,261 $91.14 1
2021 Q3 269,238 $22,468,000 +$4,076,882 $83.45 1
2021 Q2 220,384 $20,081,000 -$11,096,743 $91.12 1
2021 Q1 342,168 $26,909,000 -$1,832,045 $78.64 1
2020 Q4 361,405 $31,273,140 +$15,622,035 $90.35 2
2020 Q3 179,877 $15,266,319 +$1,832,606 $85.79 2
2020 Q2 158,244 $13,771,662 +$2,120,677 $87.01 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .